Voyager Therapeutics (VYGR)

• Market cap: $192M
• 1 day: -1.70%
• 5 days: 10.86%
• 1 month: -6.72%
• 3 months: -38.37%
• 6 months: -48.59%
• Year to date: -41.88%
• 1 year: -53.23%
• 5 years: -69.85%
• 10 years: -80.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 172

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

19% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 37

2% more funds holding

Funds holding: 128 [Q3] → 130 (+2) [Q4]

1.27% less ownership

Funds ownership: 64.44% [Q3] → 63.16% (-1.27%) [Q4]

5% less capital invested

Capital invested by funds: $206M [Q3] → $196M (-$10.4M) [Q4]

42% less call options, than puts

Call options by funds: $273K | Put options by funds: $474K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 188% upside
• Avg. target: $17.33 400% upside
• High target: $30 765% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 21% 1-year accuracy 40 / 187 met price target	765% upside $30	Buy Reiterated	8 Apr 2025
Canaccord Genuity Sumant Kulkarni 7% 1-year accuracy 2 / 29 met price target	246% upside $12	Buy Maintained	13 Mar 2025
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target	188% upside $10	Overweight Maintained	12 Mar 2025